Navigation Links
Hormone Replacement Therapy increases the risk of endometrial cancer

Hormone Replacement Therapy (HRT) is a common treatment procedure for postmenopausal women who want to get back to a normal life. Currently HRT had been under a lot of flak// as time and again it has been associated to heath risks. The newest health risk of the treatment is the risk of endometrial cancer.

Endomertial cancer is the cancer that forms in the endometrial lining of the uterus. This form of cancer is found mostly in postmenopausal women.

The research came out in the current issue of The Lancet, as part of a greater study called Million Women Study. The researchers had studied more than 70,000 postmenopausal women in UK without previous cancer or previous hysterectomy.

Of the 45% women who had used the HRT, the risk of having endometrial cancer was greater for women who had taken oestrogens and tibolone in their treatment. Hormone progestagens did counteract the unfavorable effect of oestrogens on the endometrium. However, the combined effects of oestrogen-progestagen HRT had increased the risk of breast cancer in women.

When the combined risks of both breast cancer and endometrial cancer are taken together, the results show a greater incidence of cancer with the combination HRT, both in continuum and cyclic, than compared to other therapies.
'"/>




Page: 1

Related medicine news :

1. Levothyroxine Thyroid Hormone Replacement, Approved for Hypothyroidism
2. Hormone replacement Therapy a headache
3. Ovarian cancer in relationship with Hormone therapy
4. Hormone contraceptives lead to bone problems
5. Hormone treatment helps obese people slim down
6. Hormone Deficiency Results In Miscarriage
7. Hormones Linked To Migraines
8. Hormone replacement therapy helps women
9. Decrease of Hunger Hormone after Obesity Surgery
10. Possible benefits of Hormone Replacement Therapy
11. Hormone replacement therapy improves sexual function
Post Your Comments:
Breaking Medicine News(10 mins):Health News:Children's Hospital Surgeon Receives Prestigious Paul Tessier Medal 2Health News:Physical Therapist, Money Launderer and Patient Recruiter Plead Guilty in Connection With Multiple Detroit Health Care Fraud Schemes 2Health News:Physical Therapist, Money Launderer and Patient Recruiter Plead Guilty in Connection With Multiple Detroit Health Care Fraud Schemes 3Health News:Physical Therapist, Money Launderer and Patient Recruiter Plead Guilty in Connection With Multiple Detroit Health Care Fraud Schemes 4Health News:Authentidate Holding Corp. Completes Capital Raise 2Health News:Authentidate Holding Corp. Completes Capital Raise 3Health News:Happy Feet are Healthy Feet: Common Sense Tips on Taking Care of Your Feet to Survive the Holiday Season 2Health News:Concord Medical Services Holdings Limited Announces Pricing of Initial Public Offering on the New York Stock Exchange 2Health News:Concord Medical Services Holdings Limited Announces Pricing of Initial Public Offering on the New York Stock Exchange 3
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8Watson Pharmaceuticals Receives FDA Approval for Generic PLAN B 28R 29 for Over the Counter Use 55640 1Watson Pharmaceuticals Receives FDA Approval for Generic PLAN B 28R 29 for Over the Counter Use 55640 2Meat Dairy Wont Up Odds for Breast Cancer 55638 1Meat Dairy Wont Up Odds for Breast Cancer 55638 2Meat Dairy Wont Up Odds for Breast Cancer 55638 3Pennsylvania Health Department Distributing Potassium Iodide to People Living Working Near Nuclear Power Plants 55636 1Pennsylvania Health Department Distributing Potassium Iodide to People Living Working Near Nuclear Power Plants 55636 2Pennsylvania Health Department Distributing Potassium Iodide to People Living Working Near Nuclear Power Plants 55636 3